Skip to main content

Advertisement

Table 2 Adverse events: weeks 0 through 24

From: Change from subcutaneous to intravenous abatacept and back in patients with rheumatoid arthritis as simulation of a vacation: a prospective phase IV, open-label trial (A-BREAK)

System Number Description
Musculoskeletal 31 Arthritis/arthralgia (15), back pain (4), unspecific pain (3) osteopenia/osteoporosis (3), morning stiffness (1), tendovaginosis stenosans (1), plantar fascia pain (1), worsening fibromyalgia (1), tendinitis calcarea (1)
Infection 25 Upper airway infection (18), herpes labialis (2), fungi infection (2), fever (3)
Gastrointestinal 13 Vomiting (4), diarrhea (3), flatulence (1), diabetes mellitus (1), abdominal cramps (1), esophageal reflux (1), aphthous ulcers (1), lip blisters (no herpes proven, 1)
Neuro-psychological 14 Patient falling (4), restless legs (1), neuropathy (1), reduced leg strength (1), fatigue (1), anxiety (1), dysesthesia (1), depression (1), hyperventilation (1), involuntary movements (1), dizziness (1)
Other 7 Leg edema (2), polyp on vocal cord (2, same patient), hypokalemia (1), suspected claudicatio (1), vitamin D deficiency (1),
Dermatological 6 Exanthema (2), hematoma (2), hair loss (1), red eye (1)